This week, we dive into a sudden and pivotal regulatory shift in Brazil. ANVISA has just launched a new fast-track approval pathway for medium-risk medical devices, a move that could dramatically accelerate market entry. But this opportunity comes with a complex new requirement that is already tripping up unprepared manufacturers.

In this episode, we break down exactly what ANVISA's new resolution entails. We explore the case of a German MedTech firm whose attempt to leverage this new fast-track process was immediately halted by a documentation mistake, highlighting a critical new pain point for foreign companies. This is a must-listen for any regulatory professional eyeing the Brazilian market.

Key Questions from This Episode:

- Does your existing FDA or CE clearance automatically qualify you for ANVISA's new fast-track process?

- What is the single most common error companies are making in the new 'Comparative Regulatory Analysis' report?

- How can you leverage your existing technical file to meet the stringent new local requirements in Brazil?

- Why might your standard global registration strategy fail under this new Brazilian rule?

- What specific expertise is now essential for a successful and speedy submission to ANVISA?

- Is it possible to get your device approved in Brazil in under six months, and what's the secret?

Navigating global markets requires more than just a great product; it demands flawless regulatory execution. At Pure Global, we provide end-to-end regulatory consulting, acting as your local representative in over 30 markets, including Brazil. We combine local expertise with advanced AI tools to streamline market access, manage technical dossiers, and ensure your submission is right the first time. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.